Mohamad Alkhouli, M.D., M.B.A.

The purpose of this is to characterize the relationship between pre-procedural MCG-based, and the peri-procedural angiography-based measures. The quantitative angiographic measures may include the location(s) and extent of stenosis, TIMI flow grade, OMI vs. NOMI determination.

The purpose of this study is to assess the impact of sedation strategy on cognitive outcomes after left atrial appendage occlusion (LAAO) occlusion with the WATCHMAN FLX™ or AMULET device.

The purpose of this study is to measure the utility of Magnetocardiography (MCG) using the Mesuron Avalon-H90 MCG device in discerning underlying myocardial disease in patients presenting to the Catheterization Laboratory for coronary angiography, hemodynamic studies, or myocardial biopsy.

The aim of this multi-center study will be to assess the feasibility and safety of left atrial appendage (LAA) occlusion with the WATCHMAN™ device using a standardized intra-procedural intracardiac echocardiography (ICE) protocol under moderate sedation for procedural guidance. By eliminating the need for general anesthesia, we hope to show a reduction in procedural time, decrease use of supplemental invasive procedures (central venous line, invasive arterial pressure monitoring and transesophageal echocardiography) and quicker patient recovery time. This approach can decrease healthcare resource utilization and safely simplify left atrial appendage closure with the WATCHMAN device.

The purpose of this study is to evaluate the safety and effectiveness of the Amulet 2 device in patients who have non-valvular AF at increased risk for stroke and systemic embolism and who are suitable for short-term anticoagulation therapy.

The purpose of this study is to establish the safety and effectiveness of the Edwards SAPIEN 3 Transcatheter Heart Valve in patients who have  severe, symptomatic aortic stenosis and are at low operative risk for standard aortic valve replacement.

This clinical trial is a prospective, randomized, controlled, multi-center study. Patients will be randomized 1:1 to receive either transcatheter aortic valve replacement (TAVR) with the Edwards SAPIEN 3 THV or clinical surveillance. Patients will be stratified by whether or not they are able to perform a treadmill stress test. Patients who have a positive stress test will be followed in a registry to collect data on subsequent treatment and mortality, as applicable.

To assess the safety and effectiveness of the SAPIEN 3/SAPIEN 3 Ultra (Edwards Lifesciences, Irvine, California) transcatheter heart valve in patients with a failing aortic bioprosthetic valve.

The purpose of this study is to assess the safety and effectiveness of the SAPIEN 3 (Edwards Lifesciences, Irvine, California) transcatheter heart valve in patients with a failing mitral bioprosthetic valve.

The purpose of this study is to assess the severity of tricuspid regurgitation (a disorder in which the tricuspid valve in your heart does not close tight enough) using cardiac magnetic resonance imaging (MRI).

The purpose of this trial is to determine the safety and effectiveness of the Edwards SAPIEN XT and the Edwards SAPIEN 3 transcatheter heart valve and delivery systems which are intended for use in patients with symptomatic, calcific, severe aortic stenosis.

The purpose of this study is to demonstrate the performance and safety of intracardiac echocardiography (ICE) system to guide cardiac interventional percutaneous procedures when used according to its instructions for use (IFU) in standard clinical practice.

The primary objective of this study is to determine if left atrial appendage closure with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants (NOACs) in patients with non-valvular atrial fibrillation.

This investigation constitutes a feasibility study involving assessing the safety and feasibility of combining clinically indicated Left Atrial Appendage Occlusion (LAAO) and Transcatheter Mitral Valve Repair (TMVR) in one setting using approved devices.